Insider

Bristol Myers Squibb reported $13.1 billion in revenue for the third quarter of 2026

Bristol Myers Squibb generated $13.1 billion in total net revenue for the third quarter of 2026, compared to $12.2 billion for the same period in 2025. In addition to its financial results, the company reported regulatory approvals and positive interim clinical trial results from its pipeline.

Verified against 5 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white and black plastic bottle lot
Photo by Testalize.me on Unsplash
$13.1 billion
Quarterly revenue
68.3%
Gross margin
$1.05
GAAP diluted EPS

Key points

  • GAAP diluted earnings per share (EPS) was $1.05 for the third quarter of 2026, down from $1.08 a year earlier.
  • The company stated there are no guarantees that it will achieve its strategic goals or that its pipeline products will be commercially successful.

Financial results and portfolio expansion

GAAP diluted earnings per share (EPS) was $1.05 for the third quarter of 2026, down from $1.08 a year earlier. The gross margin fell to 68.3% from 71.9% last year. The company attributed the decline to a change in product mix and one-time charges related to a contract termination.

The FDA approved Zenbexus to treat multiple myeloma in adult patients who have received at least one prior line of therapy. The company also received expanded approval for Camzyos, which is now indicated for symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients weighing 30 kg or more.

Revenue by quarter, $B

12.3Q4 '24*11.2Q1 '2512.3Q2 '2512.2Q3 '2512.5Q4 '25*11.5Q1 '2613Q2 '2613.1Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Risks and uncertainties

The company stated there are no guarantees that it will achieve its strategic goals or that its pipeline products will be commercially successful. Its 2026 financial guidance excludes potential future acquisitions, divestitures, and other unforeseen costs. Additionally, competition from generic drugs continues to grow in the U.S. market, specifically for the drugs lenalidomide and pomalidomide.

What to watch

Investors should monitor further regulatory decisions regarding company products and clinical trial results published in current event reports. The successful commercialization of new drugs, such as Zenbexus and Camzyos, remains a key factor for financial performance, as there is no certainty regarding future clinical trial outcomes or the timing of regulatory approvals.

Original sources

  1. 8-K EX-99.1 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 32fa48013a8f…
  2. 8-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 560c89f97ad9…
  3. 8-K EX-99.2 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy bbdce4314c7e…
  4. 10-Q risk factors compared with the 10-Q filing, July 30, 2026October 29, 2026SHA-256 of our archived copy eddeb588d59b…
  5. financial data (XBRL)October 29, 2026SHA-256 of our archived copy 75ae038acf2d…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards